Cost Dynamics in HIV
How an Aging Population will Change the Market
As a result of enhancements in antiretroviral therapy, HIV has transitioned from an inevitably fatal condition into a manageable, chronic disease.
This white paper explores the changing cost dynamics seen in HIV prescription payment and the potential implications this evolution may have on key U.S. healthcare stakeholders.
Learn more about Amundsen Consulting